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Current therapeutic options for treating colorectal cancer have little clinical efficacy and
acquired resistance during treatment is common, even following patient stratification.
Understanding the mechanisms that promote therapy resistance may lead to the develop-
ment of novel therapeutic options that complement existing treatments and improve patient
outcome. Here, we identify RAC1B as an important mediator of colorectal tumourigenesis and
a potential target for enhancing the efficacy of EGFR inhibitor treatment. We find that high
RAC1B expression in human colorectal cancer is associated with aggressive disease and poor
prognosis and deletion of Rac1b in a mouse colorectal cancer model reduces tumourigenesis.
We demonstrate that RAC1B interacts with, and is required for efficient activation of the
EGFR signalling pathway. Moreover, RAC1B inhibition sensitises cetuximab resistant human
tumour organoids to the effects of EGFR inhibition, outlining a potential therapeutic target for
improving the clinical efficacy of EGFR inhibitors in colorectal cancer.
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Colorectal cancer (CRC) is the second commonest cause ofcancer-related mortality with highly variable disease out-come and response to therapies. Part of these differences
are believed to be due to extensive genomic and transcriptomic
heterogeneity leading to the acquisition of rapid resistance to
available treatments1. For example, the effectiveness of the anti-
epidermal growth factor (EGF) antibodies cetuximab or panitu-
mumab, which are utilised in a subgroup of KRAS wild-type
(WT) CRCs is limited, with resistance rapidly emerging via
multiple and diverse mechanisms2,3. Recent efforts to understand
CRC complexity has led to the definition of a number of distinct
consensus molecular subtypes (CMSs) based on gene expression
patterns of tumour biopsies or purified tumour epithelial cells1,4.
These different subtypes classify tumours with distinguishing
features such as microsatellite instability (MSI), high/hypermu-
tated/BRAF mutated (CMS1), WNT activated (CMS2), meta-
bolic/KRAS mutated (CMS3) and EMT/TGF-β activated (CMS4).
Classification into different subtypes provides useful predictive
information such as patient prognosis and predicted response to
therapies. For example, patients with CMS2 tumours pre-
ferentially benefit from anti-epidermal growth factor receptor
(EGFR) and anti-vascular endothelial growth factor (VEGF)
therapy5,6. However, even within CMS subtypes extensive het-
erogeneity exists and despite stratification many patients benefit
only from an initial treatment response with therapy resistance
frequently observed. Interestingly, recent evidence suggests that
resistance to the EGFR inhibitor cetuximab can be acquired by
switching molecular subtype indicating non-genetic, transcrip-
tional mechanisms may play an important role in modulating
response to therapy7. Together, this outlines a pressing need to
develop both novel therapeutic options and to also better
understand disease complexity to enable better stratification of
available treatments.
The majority of CRC cases are initiated by loss or inactivation
of the APC tumour suppressor gene with accumulated mutations
in other key pathways, such as MAPK, TP53 and TGF-β pro-
moting tumour progression8–10. APC is a negative regulator of
the WNT signalling pathway that when lost, allows β-catenin to
accumulate in the nucleus and drive an oncogenic transcription
programme leading to tumour formation11,12. Previous studies
have identified the WNT target gene Myc as a key mediator of
oncogenic WNT signalling and demonstrated reduced MYC
levels perturbs intestinal tumorigenesis13,14. MYC has long been
proposed as a therapeutic target for multiple cancer types but
direct inhibition of the protein has proven difficult owing to a
lack of defined ligand binding sites. However, a number of
pathways regulated by MYC signalling have subsequently been
shown to be important for efficient tumorigenesis following APC
loss demonstrating alternative mechanisms by which the outputs
of oncogenic WNT signalling may be targeted15–20.
We previously identified one such pathway, RAC1 signalling, as
being critical for the expansion of intestinal stem cells and sub-
sequent tumour formation following Apc deletion in the mouse19.
Activation of RAC1 is achieved by binding of Rho-Guanine
Exchange factors (GEFs) and we previously identified upregulation
(and subsequent RAC1 activation) of a number of these following
Apc loss19. An alternative mechanism via which RAC1 signalling
can be activated is via the splice variant termed RAC1B, which is
overexpressed in numerous tumour types21. RAC1B results from
the inclusion of exon 4 (alternatively designated exon 3b) encoding
an additional 19 amino acids which leads to constitutive
activation22–24. It is believed that RAC1B has a distinctive, more
restricted set of effector pathways than RAC1, but appears to be
more critical for tissue transformation25–29. Despite some in vitro
evidence supporting a tumorigenic role for RAC1B, its in vivo
function and mechanism of action is poorly understood and to date
no studies have assessed whether RAC1B is required for tumor-
igenesis in vivo and thus the potential benefits of its therapeutic
targeting.
We therefore set out to determine the requirement for RAC1B
during intestinal tumorigenesis. Here we find that RAC1B is
overexpressed in CRC and high RAC1B expression correlates with
high WNT activity and poor prognosis. We find that deletion of
Rac1b in a mouse model of intestinal cancer significantly
increases survival and reduces tumour number, tumour-cell
proliferation and tumorigenic WNT signalling. Mechanistically,
RAC1B interacts with a network of membrane-bound receptor
tyrosine kinases (RTKs) including the important oncogenic
mediators EGFR and ERBB2. RAC1B is required for efficient
activation of EGFR signalling and organoid cultures lacking
Rac1b are sensitised to EGFR inhibition. Importantly, cetuximab-
resistant human tumour organoids treated with a novel inhibitor
of RAC1B splicing show this same increased sensitivity to EGFR
inhibition suggesting RAC1B may be a candidate therapeutic
target for co-treatment with EGFR inhibitors in CRC.
Results
RAC1B overexpression correlates with high WNT activity and
poor prognosis in human CRC. To investigate the expression of
RAC1B in human CRC, we analysed previously determined
percent spliced in (PSI) values of RAC1B exon 4 from TCGA
RNAseq experiments30. In line with previous reports, this
demonstrated a significant increase in RAC1B expression in
human colorectal tumours (Fig. 1A). We confirmed this using
isoform expression data obtained directly from TCGA RNAseq
dataset (Fig. S1A). We also observed significantly increased
RAC1B expression in advanced stage (TIII and TIV) compared to
early stage (TI and TII) disease, in patients with lymphovascular
tumour invasion and in patients with metastatic disease (Fig. 1B).
Tumours were classified as high or low for RAC1 expression
taking as reference the thresholds for PSI values described
previously21. Using a stringent threshold we designated three
groups: RAC1Bhigh (delta PSI > 0.2 above normal tissue average,
~18% of tumours), RAC1Blow (PSI value lower than normal tissue
average, ~7% of tumours) and RAC1Bint (intermediate expres-
sion, ~75% of tumours) (Fig. S1B). Confirming our expression
analysis, tumours in the RAC1Bhigh group were significantly more
likely to be found at a more advanced stage and with presence of
lymphovascular invasion than tumours in the RAC1Blow and
RAC1Bint groups (Fig. S1C, D). Furthermore, high levels of
RAC1B expression were correlated with significantly reduced
disease-free (hazard ratio of 2.64) and lower overall survival
(hazard ratio of 2.08) (Fig. 1C). These data demonstrate that
elevated levels of RAC1B correlates with poorer disease outcome
in CRC.
To determine whether high RAC1B expression was associated
with a particular CRC CMS, we correlated expression of RAC1B
with the gene classifier sets for each individual subtype. RAC1B
expression was positively correlated with the majority of genes
that classify the CMS2 subtype and negatively correlated with the
majority of genes that classify the CMS1 subtype (Figs. 1D and
S1E). Little enrichment for either the CMS3 or the CMS4 subtype
was observed. Further analysis of the transcriptional profile of
RAC1B in this dataset confirmed these observations with tumours
classified as CMS1 expressing low levels of RAC1B and tumours
classified as CMS2 expressing high levels of RAC1B (Figs. 1E and
S1F). Additionally, we found that RAC1Bhigh tumours were most
common in CMS2 tumours, although notably also present in
CMS4 (Fig. S1G, H). Furthermore, GSEA carried out on
RAC1Bhigh vs RAC1Blow expressing tumours confirmed the
positive enrichment of genes associated with the CMS2 subtype,
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other gene sets associated with WNT signalling activation and a
negative enrichment of genes associated with the CMS1 subtype
(Fig. S1I). Validating these findings, we found expression of
canonical WNT target genes AXIN2, LGR5, TCF7 and ASCL2
were elevated in tumours expressing high levels of RAC1B
(Figs. 1F and S1J). The same analysis revealed significantly lower
expression of RAC1B in MSI tumours and/or tumours carrying
mutations in BRAF as hypothesised by the negative correlation
with CMS1 (Fig. S1K). These data indicate RAC1B expression
correlates with high levels of WNT signalling in human CRC.
Apparently contradictory to these findings, the prognosis of
patients with WNT-activated CMS2 tumours is relatively good
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with CMS4 tumours resulting in the worst overall survival1. As
RAC1Bhigh tumours are also found in CMS4 it is possible that
these tumours are responsible for the poor prognosis identified for
RAC1Bhigh tumours. To investigate this further, we plotted the
outcome of patients with CMS2 tumours only, split according to
RAC1B-expression levels. This analysis demonstrated that patients
with CMS2 tumours could be separated based on RAC1B
expression with high levels of RAC1B conferring survival
outcomes as poor as patients with the highly aggressive
mesenchymal CMS4 subtype tumours (Fig. 1G). Therefore, a
significant proportion of CMS2 tumours have poor prognosis and
these are marked by high levels of RAC1B expression. Together,
these data demonstrate that high RAC1B expression marks a
subset of tumours with high WNT activity and poor patient
outcome suggesting an important role in colorectal tumorigenesis.
Rac1b is expressed in mouse intestinal crypts and its expres-
sion is increased following Apc deletion. We next examined the
expression of Rac1b in mouse intestinal tissue. To do so, we frac-
tioned intestinal epithelium into villus and crypt / crypt base frac-
tions (Fig. 2A). Expression analysis of stem and progenitor cell
markers validated the fractionation protocol (Fig. S2A). Interest-
ingly, whilst Rac1 was fairly uniformly expressed across all fractions,
Rac1b showed significantly higher expression in the crypt fractions,
indicative of high expression in proliferative intestinal cells (Figs. 2B
and S2A). To investigate whether Rac1b expression is enriched in
intestinal stem cells, we sorted Lgr5+ cells from mice carrying the
Lgr5-EGFP-ires-CreERT2 transgene (Fig. S2B). Consistent with our
fractionation experiments, we found increased Rac1b expression in
Lgr5+ compared to Lgr5- cells (Fig. 1C). To confirm these obser-
vations we designed a RNA in situ hybridisation BaseScope probe
to detect Rac1b expression (exon 4–5 junction) (Figs. 2D and S2C).
We detected low Rac1b-expression levels in mouse small intestine
(SI) and large intestine (LI) with significantly higher expression
observed in the crypts than the villi of the small intestine (Figs. 2D,
E and S2C, D). Positional scoring of Rac1b-positive signal along the
crypt villus axis confirmed Rac1b expression was found primarily in
the crypt region (Fig. S2E). However, expression was not restricted
to the crypt base suggesting Rac1b expression is enriched in pro-
liferative crypt cells but is not a specific marker of Lgr5+ stem cells
(Fig. S2E). Tissue from induced VilCreERT2 Rac1bfl/fl mice (descri-
bed later) was completely lacking hybridisation signal demonstrat-
ing the specificity of the BaseScope probe (Fig. S2C). To determine
the effects of constitutive WNT signalling activation on Rac1b
expression, we deleted Apc from the mouse small and large intestine
(by tamoxifen induction of VilCreERT2 Apcfl/fl mice and analysis
5 days later) and stained for Rac1b. Rac1b signal was increased in
crypts and villi in both tissues indicating increased Rac1b expression
following Apc deletion (Figs. 2D–F and S2C, D). Immunohisto-
chemical analysis of β-catenin indicated increased Rac1b expression
in the villus of Apc-deleted intestines correlated with nuclear
accumulation of β-catenin (Fig. S2F). Again, tissue from induced
VilCreERT2 Apcfl/fl Rac1bfl/fl mice was almost completely negative
for hybridisation signal (Fig. S2C). We also found significant
overexpression of Rac1b following Apc deletion using qRT-PCR
(Fig. S2G). These data demonstrate that Rac1b expression is
increased following Apc deletion and correlates with WNT signal-
ling activation, consistent with data from human tumours.
Rac1b deletion attenuates intestinal tumorigenesis and
tumorigenic WNT signalling. To test the functional significance
of Rac1b expression in intestinal tumorigenesis we generated mice
carrying a novel floxed allele permitting deletion of Rac1 exon 4
(Rac1bfl) (Figs. 3A and S3A) and bred these mice onto the
tamoxifen-inducible VilCreERT2 Apcfl/+ intestinal cancer model31.
In this model, tamoxifen induction leads to intestinal specific loss
of a single copy of the Apc gene. When aged, stochastic loss of the
WT Apc allele leads to tumour formation in the small and large
intestines. We generated cohorts of VilCreERT2 Apcfl/+ (Apc) and
VilCreERT2 Apcfl/+ Rac1bfl/fl (Apc Rac1b) mice, induced them
with tamoxifen and aged them until clinical signs of intestinal
tumorigenesis became apparent. Deletion of Rac1b significantly
increased tumour-free survival compared to WT controls (med-
ian survival 138 vs 171 days) (Fig. 3B). Macroscopic and histo-
logical analysis of the intestines of these mice also revealed a
significant reduction in average tumour number (54 vs 27)
(Fig. 3C–E). Analysis in different regions of the intestine revealed
a significant reduction in tumour number in the duodenum and
jejunum, but not in the ileum or colon (Fig. S3B). qRT-PCR
analysis demonstrated a significant increase in Rac1b expression
in small intestinal tumours arising in Apc mice confirming our
observations that WNT signalling activation increases Rac1b
expression (Fig. S3C). Interestingly, analysis of tumours harvested
from Apc Rac1b mice did not show the expected reduction in
Rac1b expression, and analysis of individual tumours indicated
around half of small intestinal and all colonic tumours expressed
higher levels of Rac1b than normal intestinal tissue (Fig. S3C, D).
This indicated a failure to efficiently delete Rac1b suggesting a
positive selective pressure for maintaining Rac1b expression in
tumour-initiating cells. Phenotypically, tumours from Apc and
Apc Rac1b mice had comparable histological appearance with
similar levels of apoptosis (as measured by Caspase 3
Fig. 1 RAC1B overexpression correlates with tumour progression and poor prognosis in human CRC. A Individual value plot of RAC1B exon 4 PSI values
for normal and colorectal tumour tissue (TCGA dataset) (data are presented as mean ± SD; ****P= 2 × 10−15; two-tailed t-test, n= 41 vs 457 tumour
samples). B Individual value plots of RAC1B exon 4 PSI values from TCGA CRC dataset comparing: early (TI&II) vs late (TIII&TIV) stage CRC (left panel)
(data are presented as mean ± SD; **P= 0.0029; two-tailed t-test, n= 227 vs 179 tumour samples), absence vs presence of lymphovascular invasion
(middle panel) (data are presented as mean ± SD; **P= 0.004; two-tailed t-test, n= 241 vs 162 tumour samples) and absence (M0) or presence (M1) of
metastasis (right panel) (data are presented as mean ± SD; ***P= 0.0008; two-tailed t-test, n= 329 vs 136 tumour samples). C Disease-free (top panel)
and overall (bottom panel) survival of human CRC patients separated by high vs low/intermediate RAC1B expression. Log-rank P value, hazard ratio (HR)
and 95% confidence intervals (CI) presented. D Bar plots of Pearson’s correlation coefficients for RAC1B exon 4 PSI values and genes that identify different
CRC CMSs. Each bar corresponds to the correlation of RAC1B and an individual gene, red bars indicate genes positively correlated with RAC1B and blue bars
genes negatively correlated with RAC1B expression (P < 0.05). E Individual value plots of RAC1B exon 4 PSI values in tumours from each CMS compared to
all other tumours. CMS1 vs all; data are presented as mean ± SD; ****P= 4.83 × 10−13; two-tailed t-test, n= 71 vs 299 tumour samples. CMS2 vs all; data
are presented as mean ± SD; ****P= 5.49 × 10−6; two-tailed t-test, n= 145 vs 225 tumour samples. CMS3 vs all; data are presented as mean ± SD, n= 54
vs 316 tumour samples. CMS4 vs all; data are presented as mean ± SD, n= 100 vs 270 tumour samples. F Individual value plots of WNT target gene
expression in tumours expressing low vs high RAC1B. AXIN2; data are presented as mean ± SD; ***P= 0.0005; two-tailed t-test, n= 22 vs 60 tumour
samples. LGR5; data are presented as mean ± SD; ***P= 0.0004; two-tailed t-test, n= 22 vs 60 tumour samples. G Disease-free survival of human CRC
patients with tumours from the CMS2 CRC subtype separated by high vs low/intermediate RAC1B expression. Survival of patients with CMS4 CRC subtype
tumours included for comparison. Log-rank P value shown. Source data are provided as a Source Data file.
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immunohistochemistry, IHC) and similar numbers of Paneth and
Goblet cells (Fig. S3G, H). However, tumours from Apc Rac1b
mice were significantly less proliferative than controls (Fig. 3F,
G). To determine whether there is a direct association between
RAC1B and tumour-cell proliferation, we used Rac1b Basescope
to identify tumours from our Apc Rac1b mice that had not effi-
ciently deleted Rac1b (Fig. S3E, F). By staining these tumours for
BrdU incorporation, we found that these tumours proliferate
significantly better than those that are Rac1b-negative and to a
similar extent as tumours from Apc control mice (Fig. S3E, F).
Thus, Rac1b expression is required for efficient tumour-cell
proliferation. Importantly, Rac1b deletion in normal adjacent
tissue was maintained for the duration of the experiment
(~6 months) in all mice analysed (Fig. S3C, D), and cell pro-
liferation, apoptosis, Paneth cell and goblet cell populations were
unchanged suggesting Rac1b deletion is well tolerated in normal
intestinal tissue (Fig. S3I, J). In addition, analysis of Rac1
expression indicated this was mostly unaffected by deletion of
Rac1b exon 4 demonstrating the specificity of our knockout allele
(Fig. S3K). To further investigate the tumorigenic phenotype, we
utilised an ex vivo organoid clonogenic culture method to
determine the tumour-initiating capacity of Apc-deficient cells in
the absence of Rac1b expression (Fig. S3L, M). We generated
intestinal organoid cultures from mice following acute
Fig. 2 Rac1b is expressed in intestinal crypt cells and its expression increases following Apc deletion. A Schematic outlining crypt extraction protocol.
B qRT-PCR of Rac1b from villus and crypt fractions (data are presented as mean ± SD; **P= 0.0018, ***P= 0.0005; one-way ANOVA with Tukey multiple
correction, n= 3 biologically independent mice). C qRT-PCR of Rac1b from sorted Lgr5+ and Lgr5- cells (data are presented as mean ± SD; *P= 0.0117; two-
tailed t-test, n= 3 biologically independent mice). D Representative images of Rac1b basescope ofWT and Apcfl/fl small intestinal tissue. Magnified areas are
shown in right panels. Pink dots are positive probe detection. Scale bars are 100 µm (left panels) and 25 µm (magnified). E Quantification of Rac1b basescope
probe counts comparing WT vs Apcfl/fl small intestine separated by villus and crypt regions (data are presented as mean ± SD; *P= 0.018, **P= 0.0034,
****P= 4 × 10−6 (WT vs Apcfl/fl villus), ****P= 8.62 × 10−6 WT vs Apcfl/fl crypt); two-way ANOVA with Tukey multiple correction, n= 3v3 biologically
independent mice. For each mouse, at least five areas for crypt and villus regions were scored. In total, these areas incorporated at least 50 crypt/villus axes
and covered ~2mm2 total area). F Quantification of Rac1b basescope probe counts comparing WT vs Apcfl/fl across the entire small intestine (data are
presented as mean ± SD; ****P= 5.47 × 10−6; two-tailed t-test, n= 3v3 biologically independent mice). Source data are provided as a Source Data file.
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homozygous deletion of Apc and Rac1b (Apcfl/fl and Apcfl/fl
Rac1bfl/fl), digested them to single cells and determined their
clonogenic capacity. Interestingly, the ability of Apc-deficient cells
to form colonies from single cells was significantly reduced by
Rac1b deletion (Fig. 3H). Together, these data demonstrate an
important role for Rac1b expression during WNT-mediated
intestinal adenoma formation.
To identify potential pathways mediated by Rac1b expression
involved in tumorigenesis, we carried out RNAseq analysis on 4
vs 4 small intestinal tumours dissected from Apc and Apc Rac1b
mice (confirmed negative for Rac1b by qRT-PCR). This analysis
identified 506 mRNAs with significantly altered expression (fold
change > 1.5, padj < 0.05). Of these, 265 had significantly
increased expression and 241 had significantly decreased
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expression (Supplementary Data 1). Pathway analysis of our
dataset identified regulation of immune response, antigen
processing and viral response amongst the most upregulated
pathways indicating a role for Rac1b in regulating these processes
(Fig. 4A). Interestingly, amongst the most significantly down-
regulated pathways were the canonical WNT signalling pathway
and WNT-protein binding (Fig. 4A). Furthermore, GSEA
demonstrated significant enrichment of genes downregulated in
our RNAseq dataset with gene sets associated with WNT
signalling activation (Fig. 4B, C). We used qRT-PCR to validate
the differential gene expression of some of the identified stem
cell/ WNT target genes in Rac1b deficient (Fig. 4D). There was no
significant expression changes in any of these target genes in
normal tissue from the same mice suggesting the requirement for
Rac1b is specific to tumour cells. Intestinal tumours arising in Apc
Rac1b mice demonstrated strong, nuclear β-catenin positivity
suggesting a role for RAC1B downstream of β-catenin nuclear
localisation (Fig. S4A). This is in agreement with our previous
findings that β-catenin operates upstream of RAC1 signalling in
promoting intestinal tumorigenesis19. Alongside our analysis of
human TCGA data, these findings suggest a key role for RAC1B
in regulating tumorigenic WNT signalling in CRC.
RAC1B interacts with core components of the EGFR signalling
pathway. To better understand the mechanism by which RAC1B
mediates intestinal tumorigenesis, we sought to identify its
interacting proteins using proximity-dependent biotin identifi-
cation (BioID) (Fig. 5A). We overexpressed RAC1 and RAC1B
proteins fused to the BirA ligase (and BirA-only controls) in the
mouse rectal tumour cell line CMT93, treated with biotin fol-
lowed by streptavidin capture and identified enriched proteins by
mass spectrometry. Here, 60 enriched proteins were identified
(Supplementary Data 2) with both RAC1 and RAC1B having
highly similar interactomes (50 common interactors, and only
2 specific to RAC1 and 8 specific to RAC1B) (Fig. 5B). Pathway
analysis of identified proteins demonstrated enrichment in
adherens junctions, focal adhesions and localisation to the plasma
membrane (Fig. S5A). We used NetworkAnalyist and the IMEx
interactome database to visualise the protein–protein interactions
of the identified proteins. This analysis identified 7 protein sub-
networks with the major network clustered around membrane
localised components of oncogenic signalling pathways (Fig. 5C).
This network contained core members of the EGFR/ERBB
(EGFR, ERBB2), IGF (IGF1R), SRC (YES1) and EPH (EFNB2)
signalling pathways. Further analysis of identified proteins indi-
cated other EGFR-related signalling components such as ASAP1
and PTPRJ32,33. A number of proteins with links to the WNT
signalling pathway were also identified, such as CCNY, which
activates WNT signal through LRP6 receptor phosphorylation34,
and PROM1, a marker of intestinal stem/progenitor cells and
colon cancer stem cells35–37. However, no members of the core
receptor and/or destruction complex were identified indicating
that, in our model, RAC1B may not function directly in the WNT
signalling pathway. Interestingly, several reports have highlighted
potential crosstalk between EGFR and WNT signalling
pathways38,39. Additionally, the EGFR signalling pathway is a
therapeutic target in CRC, so the involvement of RAC1B on its
activity may have implications for the treatment of this disease.
Therefore, we chose to investigate the relevance of the identified
RAC1B–EGFR pathway interaction. We first validated the
interaction between RAC1B and EGFR. The BioID experiment
was repeated by treating BirA- and BirA-RAC1B-transfected
CMT93 cells with biotin followed by streptavidin-dependent pull-
down. Western blot analysis of the pull-down fractions confirmed
efficient, specific biotinylation of EGFR by BirA-RAC1B and not
BirA control (Fig. S5B). Thus, EGFR and RAC1B are either
interacting or neighbouring proteins in CRC cells.
RAC1B is required for efficient stimulation of EGFR signal-
ling. We next determined whether RAC1B is required for EGFR
and downstream signalling. We designed an antisense oligonu-
cleotide to bind the putative exon splice enhancer of Rac1 exon 4
to disrupt the inclusion of this exon. Vivo-Morpholinos targeting
exon 4 (Rac1b PMO) demonstrated efficient in vitro knockdown
efficacy with ~95% reduction in Rac1b transcript compared to
treatment with a non-targeting, control Vivo-Morpholino (NT
PMO) (Fig. S5C). Total Rac1 transcript levels were not sig-
nificantly altered following this treatment indicating specific
inhibition of exon 4 inclusion without knockdown of total tran-
script (Fig. S5C). To determine the effects of Rac1b depletion on
EGFR signalling, CMT93 cells were pre-treated with NT or Rac1b
PMO for 2 days and then treated with 20 ng/ml EGF after serum
starvation. Samples were collected for analysis 5, 10, 15 and 30
min after treatment and untreated cells grown in 10% serum or
following starvation were used as controls. In control cells p-
EGFR levels rapidly increased, reaching a peak at 10 min post
treatment. Rac1b-deleted cells presented a reduction in the
phosphorylated status of EGFR, implying lower levels of activa-
tion (Fig. 5D, E). This difference in p-EGFR was most apparent
10 min post stimulation and Rac1b PMO-treated cells never
reached a level of phosphorylation as high as the NT PMO. To
determine whether decreased EGFR phosphorylation translated
into lower downstream EGFR pathway activation, we assessed
ERK1/2 and AKT phosphorylation and found both proteins were
less phosphorylated in Rac1b PMO-treated cells compared to
controls (Fig. S5D, E). Replicate experiments performed in
serum-starved cells with EGF treatment for 10 min confirmed
these findings (Fig. S5F, G). Next, we sought to determine whe-
ther Rac1b regulates EGFR signalling in vivo in the Rac1b-defi-
cient mice whose survival and tumorigenesis was diminished
(Fig. 3). We analysed pEGFR and pERK levels in tumours derived
from these mice and found that pEGFR levels are significantly
lower in the Rac1b-deficient tumours but pERK levels are
unchanged (Fig. S5H, I). This suggests that as tumours establish
and develop, EGFR phosphorylation remains dependent on
Rac1b expression but alternative mechanisms to activate pERK
can be utilised. We also investigated the expression of known
EGFR pathway target genes (Etv4 and Etv5). Consistent with the
Fig. 3 Deletion of Rac1b suppresses intestinal tumorigenesis and tumour-cell proliferation. A Schematic of Rac1b floxed allele. B Survival plot of Apc vs
Apc Rac1b mice. Log-rank P value shown, n= 19v17 biologically independent mice. C Representative photographs of intestines from Apc and Apc Rac1b
tumour-bearing mice. Black arrows indicate tumours. D H&E of whole intestinal rolls from Apc and Apc Rac1b mice. Box indicates magnified area. Black
arrows indicate tumours. Scale bars are 2.5 mm (top panels) and 250 µm (magnified). E Quantification of total tumour number in the intestines of Apc vs
Apc Rac1b mice (data are presented as mean ± SD; **P= 0.003; two-tailed Mann-Whitney test, n= 19v16 biologically independent mice). F BrdU IHC in
tumours from Apc vs Apc Rac1b mice. Scale bars are 100 µm (top panels) and 50 µm (magnified). G Quantification of BrdU positivity in tumours from Apc
vs Apc Rac1b mice (data are presented as mean ± SD; **P= 0.0079; two-tailed Mann-Whitney test, n= 5v5 biologically independent mice). H
Clonogenicity assays of Apcfl/fl vs Apcfl/fl Rac1bfl/fl organoids (data are presented as mean ± SD; *P= 0.0228; two-tailed t-test, n= 3v4 biologically
independent mice). Scale bars are 1000 µm. Source data are provided as a Source Data file.
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Fig. 4 Oncogenic WNT signalling is mediated by RAC1B. A Bar plot showing the top 10 significantly enriched upregulated and downregulated pathways in
tumours from Apc vs Apc Rac1b mice. B GSEA plots of WNT target gene sets comparing tumours from Apc vs Apc Rac1b mice. C Heatmap of RNAseq
expression values of WNT target genes and intestinal stem cell markers comparing tumours from Apc vs Apc Rac1b mice. D qRT-PCR analysis of various
WNT target genes comparing tumours from Apc vs Apc Rac1b mice. As controls, matched normal tissue from these mice (WT and Rac1b, respectively) are
also included (data are presented as mean ± SD; two-tailed t-test; n= 6v6 mice). Source data are provided as a Source Data file.
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Fig. 5 RAC1B interacts with multiple membrane-bound receptor tyrosine kinases. A Schematic of BioID protocol. B Venn diagram outlining RAC1 and
RAC1B interacting proteins identified by MS and the overlap between the interactomes. C Network analysis of the RAC1/RAC1B interactome. D CMT93
cells were treated with NT or Rac1b PMO, serum-starved and then stimulated with EGF for 5, 10, 15 or 30min before analysis by western blotting for
EGFRpY1068, EGFR and Vinculin (sample control blot). Representative blots shown. E EGFRpY1068 band densitometry relative to EGFR (normalised to
Vinculin) of 4 replicate time course experiments (data are presented as mean ± SEM; **P= 0.002; two-way ANOVA with Tukey multiple correction; n=
4v4). Source data are provided as a Source Data file.
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pEGFR reduction, expression of both is significantly lower in
Rac1b deficient tumours (Fig. S5J).
To provide mechanistic insight into how RAC1B controls EGFR
signalling we investigated EGFR trafficking using Alexa 555-labelled
EGF (EGF-555). Confocal analysis of EGF-555-stimulated cells
indicated that internalisation of EGF-555 was not significantly
impaired in Rac1b-depleted cells (Fig. S6A). However, the
localisation of internalised EGF-555 appeared altered. In control
cells, we observed EGF-555 foci throughout the cell, whereas in
Rac1b-depleted cells we observed them around the cell periphery
(Fig. S6B, inset panels). To investigate this in more detail, we used
live cell imaging to monitor overall endocytic trafficking of EGFR
using EGF-555. Tracking the paths of EGF-555 vesicles revealed
that the dynamic trafficking pattern in control cells was restricted
following Rac1b depletion (Fig. S6A, C). We found that both total
EGF-555 displacement and tracking velocity were significantly
lower in Rac1b depleted cells suggesting altered EGFR trafficking
(Fig. 6B, C). To investigate this further, we assessed the co-
localisation between EGFR and the early endosome marker Rab5.
In agreement with our previous observations that EGF-555
internalisation was unaffected by Rac1b depletion, EGFR co-
localisation with Rab5 endosomes following EGF-555 stimulation
was unchanged in Rac1b depleted cells (Fig. S6D). Together, this
suggests Rac1b depletion does not prevent EGF internalisation into
early endosomes but leads to an impairment of subcellular EGFR
trafficking. Following internalisation, EGFR can be either recycled
back to the cell surface to maintain signalling or directed towards
multivesicular bodies for lysosomal targeting40. To investigate
whether the absence of RAC1B promotes a shift in EGF-bound
EGFR destination fate, NT and Rac1b PMO cells were stimulated
with EGF-555 and treated with LysoTracker Green dye to identify
lysosomal compartments. In control cells, co-localisation of labelled
EGF and LysoTracker was observed from 30min post EGF
stimulation. However, Rac1b-depleted cells present significantly
more EGF-555 Lysotracker clusters starting at earlier time points
suggesting that deletion of Rac1b promotes EGFR lysosomal sorting
and receptor degradation over the recycling route (Fig. 6D, E).
Together, these data suggest RAC1B is required for efficient
trafficking and recycling of EGFR, thus potentiating its activity.
We next investigated how RAC1B modulates WNT signalling,
in particular the potential link between these signalling pathways
in intestinal cancer. Firstly, we investigated the impact of EGFR
inhibition on WNT target gene expression in Apc-deficient
organoids and found that, similar to following Rac1b deletion, a
subset of targets were downregulated (Fig. S6F). In addition, we
depleted Rac1b in Apc-deficient organoids carrying an additional
activating mutation of Kras. In these organoids, where MAPK
signalling is constitutively active, downstream of EGFR, the
depletion of Rac1b had no effect on organoid clonogenic capacity
or WNT target gene expression (Fig. S6G–J). We also investigated
the possible involvement of NF-κB signalling and ROS activity
but found these were unaltered in Rac1b deficient organoids
(Fig. S6K, L). Interestingly, we have recently shown that deletion
of a number of RacGEFs leads to reduced ROS activity in Apc-
deficient tissue, suggesting that RacGEF-activated RAC1 controls
ROS production but RAC1B does not (Pickering et al.41).
Together, these data suggest there is crosstalk between WNT
and EGFR signalling pathways in intestinal cancer and RAC1B
mediated control of EGFR signalling activation is required for
efficient WNT signalling activity.
RAC1B depletion sensitises EGFR inhibitor-resistant colorectal
cancer liver metastatic organoids to cetuximab treatment.
These results suggest that RAC1B modulates EGFR receptor and
signalling activation. To determine whether RAC1B stimulation
of EGFR signalling was an important mediator of tumorigenic
growth, we grew Apcfl/fl and Apcfl/fl Rac1bfl/fl intestinal organoids
in the presence or absence of EGF ligand. Whereas in the pre-
sence of EGF organoids from both lines grew to a comparable
size, in its absence the growth of those lacking RAC1B was sig-
nificantly perturbed (Fig. S7A). We found similar results when
the same organoid lines were treated with the EGFR inhibitor
PD153035, with Apcfl/fl Rac1bfl/fl organoids being significantly
more sensitive to this treatment (Figs. 7A, B and S7B). To
determine whether inhibition of RAC1B might cooperate with
EGFR inhibition to increase the efficacy of treatment in human
tumour organoids, we designed a Vivo-Morpholino to target
human RAC1 exon 4 (hRAC1B PMO) (Fig. 7C). We cultured
patient-derived organoids (PDOs) from a benign colonic polyp
and a stage 3 invasive tumour (T2N1M0) from a familial ade-
nomatous polyposis (FAP) patient undergoing tumour resection.
PDOs treated with hRAC1B PMO demonstrated a robust (<95%)
knockdown in RAC1B transcript and protein levels (Figs. 7D and
S7C). As before, total RAC1 transcript was not significantly
altered (Fig. 7D). To determine the effects of RAC1B knockdown
on human tumour organoid growth, we pre-treated PDOs
derived from the benign colonic polyp with hRAC1B or NT PMO,
digested to single cells and carried out clonogenicity experiments
in the continued presence of morpholino. In agreement with our
mouse in vivo and in vitro data, RAC1B depletion led to a sig-
nificant reduction in clonogenic capacity (Fig. S7D). Interestingly,
organoids derived from the more advanced invasive tumour
resected from the same patient did not show reduced clono-
genicity suggesting depletion of RAC1B alone is unable to sup-
press proliferation of later stage, more aggressive tumours
(Fig. S7E). However, removal of EGF ligand or addition of EGFR
inhibitor led to a significant reduction in growth of tumour
organoids when combined with RAC1B knockdown (Fig. S7E).
Collectively, these results indicate a functional relevance for
RAC1B-dependent EGFR regulation and suggest a potential
beneficial therapeutic effect when both are simultaneously
inhibited. To address this in a more clinically relevant model, we
obtained previously described cetuximab-resistant human CRC
liver metastatic organoids42. Two independent organoid lines
were tested, C001 and C002, both are KRAS WT, both express
high levels of RAC1B compared to the stage 3 invasive tumour
utilised above (Fig. S7F) and both show resistance to cetuximab
treatment in vitro. In addition, C002 was derived from a patient
who acquired resistance to cetuximab upon treatment. In line
with previous reports, treatment of both organoid lines with
cetuximab did not affect organoid growth (Figs. 7E, F and
S7G–J)42. However, combining cetuximab treatment with RAC1B
depletion led to a significant inhibition of organoid growth
(Figs. 7E, F and S7G–J). These results suggest the cooperation
between RAC1B and EGFR signalling we identified in our mouse
models is conserved in human CRC, and depletion of RAC1B can
enhance the potency of EGFR inhibition in cetuximab-resistant
tumours.
Discussion
Here, we demonstrate that RAC1B mediates intestinal tumor-
igenesis. Using genetic mouse models we show that RAC1B is
required for efficient formation of intestinal tumours with dele-
tion of Rac1b leading to a reduction in tumour number, reduced
tumour proliferation and decreased oncogenic WNT signalling.
We find that RAC1B interacts with EGFR, and controls the
activation of the EGFR signalling pathway by mediating its
intracellular trafficking providing a plausible mechanism for its
pro-tumorigenic functions. Using a novel inhibitor of RAC1B
splicing, we demonstrate enhanced sensitivity to EGFR inhibition
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following RAC1B depletion in cetuximab-resistant human
tumour organoids. We also find that in human CRC, high levels
of RAC1B associate with elevated WNT signalling and poor
prognosis. Together, these findings highlight an important
oncogenic function of RAC1B and suggest therapeutic targeting of
RAC1B may enhance the efficacy of EGFR inhibition.
Previous findings from in vivo models have shown that Rac1b
overexpression alone is insufficient to drive tumorigenesis in both
intestine and lung43,44, suggesting RAC1B function is important
for tumour initiation and progression in cooperation with other
oncogenic driver events. Our analysis of TCGA data is in
agreement as it shows a significant association of high RAC1B
Fig. 6 RAC1B mediates EGFR signalling and its depletion sensitises mouse tumour organoids to EGFR inhibition. A Live cell imaging of Alexa 555‐EGF
tracking with time and velocity represented as colour spectrums. Tracking started after addition of EGF-555 and was carried out for the indicated time
period. B Individual value plot of quantification of tracking distance of EGF-555-positive vesicles (median value indicated; ****P= 1.67 × 10−13; two-tailed t-
test; n= 1213 vs 658 foci). C Individual value plot of quantification of tracking velocity of EGF-555-positive vesicles (median value indicated; **** P= 6.93 ×
10−11; two-tailed t-test; n= 1213 vs 658 foci). D Representative images of live cell imaging of Alexa EGF-555 (magenta) and LysoTracker Green (green) at
indicated time points post EGF-555 addition. White arrows indicate areas of EGF-555 LysoTracker co-localisation. Co-localised foci are observed as white
dots. Scale bars are 10 μm. E Quantification of the percentage of EGF-555 foci co-localised with LysoTracker Green at indicated time points (data are
presented as mean ± SD; *P= 0.0263, **P= 0.0094 (25min), **P= 0.0094 (30min), two-way ANOVA with Tukey multiple correction; n= 3v3
independent treatment experiments). Source data are provided as a Source Data file.
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expression with later tumour stage, presence of metastatic disease
and poor prognosis. We also identified a significant correlation of
elevated RAC1B and the WNT high, CMS2 CRC subtype and a
negative correlation of RAC1B expression and the MSI high,
BRAF-mutated CMS1 subtype. Apparently contradictory to the
survival data, CMS2 subtype CRC is characterised by relatively
good prognosis1. We subsequently found that survival of patients
with CMS2 subtype tumour could be separated based on RAC1B
Fig. 7 Depletion of RAC1B in human tumour organoids sensitises to EGFR inhibition. A Representative images of Apcfl/fl and Apcfl/fl Rac1bfl/fl organoids
grown with or without the EGFR inhibitor PD153035. Scale bars are 1000 µm. B Quantification of organoid size 20 h after addition of PD153035 (data are
presented as mean ± SD; **P= 0.0061; two-way ANOVA with Tukey multiple correction; n= organoids from 3v3 mice). C Schematic outlining design of
RAC1B PMO. D qRT-PCR analysis of PDOs treated with control or RAC1B PMO (data are presented as mean ± SD; **P= 0.0019; two-way ANOVA with
Tukey multiple correction; n= 3v3 independent treatment experiments). E Representative images (left panel) and quantification (right panel) of C001
organoid PDOs treated with control or RAC1B PMO in the presence or absence of cetuximab (left panel) (data are presented as mean ± SD; **P= 0.0011;
two-way ANOVA with Tukey multiple correction; n= 4v4 independent treatment experiments). Scale bars are 1000 µm. F Representative images (left
panel) and quantification (right panel) of C002 organoid PDOs treated with control or RAC1B PMO in the presence or absence of cetuximab (left panel)
(data are presented as mean ± SD; **P= 0.0019; two-way ANOVA with Tukey multiple correction; n= 4v4 independent treatment experiments). Scale
bars are 1000 µm. Source data are provided as a Source Data file.
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expression, with the poorest prognosis in patients with high
RAC1B. This subgroup of CMS2 patients perform as poorly as
those with highly aggressive CMS4 subtype tumours suggesting a
potential role for RAC1B in promoting tumorigenesis. It is pos-
sible that RAC1B is merely a marker of WNT-activated CRC,
however, the suppression of WNT signalling in RAC1B-deficient
tumours derived from our intestinal cancer model suggests that
RAC1B is a functional mediator of WNT signalling. Another
characteristic of CMS2 tumours is a favourable response to
treatment with EGFR inhibitors. Interestingly, other CRC sub-
typing attempts have identified a WNT-activated subtype (termed
TA) with relatively good prognosis45. However, the TA subtype
contains two distinct populations that differ in their responsive-
ness to EGFR inhibitors termed TA-CS (cetuximab sensitive) and
TA-CR (cetuximab resistant). Intriguingly, the TA-CR group
displays high WNT activity and poor prognosis, similar to the
RAC1B high, CMS2 group we have identified in this study.
Therefore, it is tempting to speculate that high RAC1B expression
plays a functional role in promoting the WNT high,
CMS2 subtype and may promote characteristics of the
cetuximab-resistant TA-CR subtype. If this is the case, inhibition
of RAC1B could be of therapeutic benefit to patients with RAC1B
high, CMS2 subtype tumours.
A number of previous studies have linked RAC1 and RAC1B to
WNT signalling; so to define the mechanism by which RAC1B
modulates tumorigenesis, we investigated its interactome using
BioID. We found a number of proteins linked to WNT signalling,
including CCNY and PROM1 but no core WNT receptor or sig-
nalling components were identified. The interactions with CCNY
and PROM1 warrant future investigation but it is also possible that
RAC1B modulates alternative pathways that cooperate with WNT
signalling, to drive tumorigenesis. Of particular note was our
identification of numerous RTKs as RAC1/RAC1B interacting
proteins including the epidermal growth factor receptors EGFR and
ERBB2. Both are well-defined drivers of oncogenesis, and inhibitors
of EGFR are used clinically for the treatment of KRAS WT CRC.
Interestingly, numerous reports have identified crosstalk between
EGFR and WNT signalling. In particular, a recent study has shown
that EGFR is required for WNT signalling via FZD9B in haema-
topoietic stem cells. This study shows that phosphorylation of
FZD9B by EGFR promotes internalisation and signal transduction
of the WNT9A–FZD9B–LRP complex providing evidence of a
direct link between these pathways38. It is not clear if this
mechanism is important for receptor-independent WNT activation
such as following Apc loss, but our observations of changes to WNT
target gene expression following EGFR inhibition suggest that links
between these pathways are maintained under such conditions. In
our study, we show that RAC1B depletion attenuates EGFR phos-
phorylation and downstream phosphorylation of AKT and ERK.
Thus, efficient EGFR pathway activation requires RAC1B. Activa-
tion of EGFR signalling is controlled, in part, by the endocytic
machinery, which directs receptors towards recycling or lysosomal
sorting. Given the requirement for RAC1B to maintain EGFR
phosphorylation after EGF stimulation, we speculated that RAC1B
might interfere in EGFR intracellular dynamics. Indeed, using live
cell imaging we observed altered EGFR trafficking upon Rac1b
depletion and increased EGFR co-localisation with lysosomes.
Therefore, it appears the depletion of Rac1b modifies EGFR traf-
ficking, leading to increased lysosomal sorting and thus reduced
activity. Our findings are in agreement with other studies that have
demonstrated crosstalk between RAC1 and EGFR signalling path-
ways. For example, EGFR has been shown to activate RAC1 by
accumulating the RacGEF TIAM1 at the membrane and promoting
its GTP-bound state46. Additionally, EGF has been shown to pro-
mote RAC1B expression itself through modulation of the splicing
factor HNRNPA1 although we did not find direct evidence of this
in our model47. Together with our data, this suggests a complex
network of interacting signalling pathways where WNT signalling
can promote RAC1B expression, which in turn promotes efficient
activation of EGFR, thus driving tumorigenesis.
In this study, we have developed a novel method of modulating
RAC1B splicing in vitro using an antisense morpholino. Antisense
morpholinos have previously been utilised to induce exon skip-
ping, with the approach showing promise as a therapeutic option
for Duchenne muscular dystrophy and Spinal muscular
atrophy48. Targeting RAC1B in this way is extremely specific and
efficient, therefore, it may be a viable way of inhibiting the spli-
cing of RAC1B without disrupting the function of RAC1 itself.
The effects of RAC1B depletion in human-derived tumour
organoid cultures corresponded well with our in vivo findings.
RAC1B depletion in a benign polyp was sufficient to significantly
attenuate clonogenic capacity, but in organoid cultures derived
from invasive and metastatic tumours it had little effect. This
would likely rule out the possibility of targeting RAC1B as a
single-agent therapeutic in late stage disease. However, treating
RAC1B-depleted tumour cells with an EGFR inhibitor led to a
significant reduction in the clonogenic growth of these cells.
Importantly, we also found that depletion of RAC1B in
cetuximab-resistant liver metastatic organoids sensitised them to
cetuximab treatment. The EGFR inhibitors, cetuximab and gefi-
tinib, are utilised for the treatment of late stage KRAS WT CRC.
Although initial responses are observed in some patients, resis-
tance rapidly emerges leading to disease progression. In some
cases, resistance is driven by activation of MAPK pathway via
mutation of genes such as KRAS, NRAS, NF1 or BRAF. In others,
no obvious mutational drivers of resistance are present, suggest-
ing non-genetic drivers of resistance. Intriguingly, a recent paper
has suggested the acquisition of resistance to cetuximab can occur
via the transcriptional switching from CMS2 to CMS4 subtypes7.
CMS4 CRC is characterised by an EMT-like, TGF-β-activated
transcriptome. We observed high RAC1B expression in a pro-
portion of CMS4 tumours and it has previously been demon-
strated that RAC1B can drive EMT, suggesting a potential
functional role for RAC1B in this process49. In addition, activa-
tion of lncRNA MIR100HG-derived miR-100 and miR-125b have
been observed in CRC cells that have acquired resistance to
cetuximab50. These microRNAs promote WNT signalling acti-
vation via repression of multiple negative regulators of the
pathway suggesting WNT signalling activation may be an
important mechanism driving cetuximab resistance. Whilst our
strategy of depleting RAC1B using morpholinos remains unpro-
ven in vivo, our proof-of-principle findings that depletion of
RAC1B sensitises tumour organoids to EGFR inhibition in vitro
suggest RAC1B may be considered as a potential therapeutic
target for enhancing the efficacy of clinically used EGFR
inhibitors.
Methods
Mouse experiments. All mouse experiments were performed under the UK Home
Office regulations and all relevant ethical regulations were adhered to. The study
protocols were approved by University of Edinburgh AWERB. Mice were bred at
the animal facilities of the University of Edinburgh and the Beatson Institute, were
kept in 12 h light–dark cycles and were given access to water and food ad libitum.
Mice were maintained in a temperature- (20–26 °C) and humidity- (30–70%)
controlled environment. Mice (of both genders) were induced with tamoxifen
between the age of 6 and 12 weeks, once they had reached a minimum weight of 20
g. Mice colonies had a mixed background (50% C57Bl6J, 50% S129). The genetic
alleles used for this study were as follows: vil-Cre-ERT2 51, Apcfl 52 and Rac1bfl.
Mice were genotyped by Transnetyx (Cordoba, USA). To achieve deletion of
RAC1B protein without affecting RAC1 expression, loxP sites were inserted on
either side of exon 4 of the mouse Rac1b transcript (Rac1-202;
ENSMUST00000100489.3; Chromosome 5: 143,509,597 – 143,509,653). Details are
given in “Supplementary Materials and Methods”. For long-term Cre recombina-
tion in tumour cohorts, mice were induced with a single intraperitoneal (IP)
injection of 80 mg/kg of tamoxifen and were aged until symptomatic of disease
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(rectal bleeding, weight loss, hunched position and/or pale feet). For short-term
Cre recombination, two consecutive IP doses of 120 mg/kg and 80 mg/kg of
tamoxifen were administrated to the mice and they were sacrificed at day 5 post
induction. Mice were randomly distributed by sex and age and a minimum of 15 or
3 mice were used for long- and short-term experiments, respectively. Proliferation
was evaluated by a single IP injection of 200 µl of BrdU cell proliferation label (GE,
1392253) 2 h prior to termination. In long-term tumour cohort mice, tumour
number and burden were macroscopically quantified in situ after mouse
termination.
Analysis of TCGA data. For isoform expression analysis of the TCGA COAD
dataset, normal and matched tumour tissue expression data of RAC1 (uc003spx.3)
and RAC1B (uc003spw.3) isoforms were downloaded from the TCGA Synapse
group (accession doi:10.7303/syn300013) and the
IlluminaHiSeq_RNASeqV2 study. For RAC1B PSI analysis, data from each tumour
type containing normal tissue expression were downloaded from the TCGASpli-
ceSeq web-based platform30. RAC1B high and low groups were categorised
according to whether PSI value was above 0.2 of normal tissue PSI average (high)
or below the average of normal tissue PSI (low). Information about patient survival,
lymphovascular invasion and metastasis was extracted from CBioPortal (cbio-
portal.org), as well as the mutational data of TCGA tumours and their CMS
classification. For CMS and RAC1B correlation analysis, RSEM-calculated reads of
TCGA COAD tumours’ dataset were downloaded from Wang et al. study53 and
genes of each CMS subtype were correlated to its RAC1B PSI value. Moreover, the
expression of some genes of interest was grouped according to RAC1B high or low
tumours. Tumour stage data, MSI status and the presence of BRAFV600E mutation
were acquired from the clinical data published by the CRC Subtyping Consortium
(CRCSC) (accession doi: 10.7303/syn2623706).
RNA sequencing and analysis. Following RNA isolation using Qiagen RNeasy
Mini Kit from intestinal tumours, RNA integrity was evaluated on an Agilent 2200
Bioanalyser and a RIN over 8 was considered optimal for analysis. Illumina
RNAseq and library preparation were performed by Edinburgh Genomics (UK).
Transcript abundances were quantified using kallisto54 from a transcriptome index
compiled from coding and non-coding cDNA sequences defined in GRCm38
(Ensembl 95). Differential expression was called using DESeq255 at the gene level
after importing estimated counts per transcript from kallisto using tximport56.
Significant genes were considered for pathway analyses using the Innate DB
database (innatedb.com). Genes were pre-ranked and analysed for Gene Set
Enrichment Analysis (GSEA, v3.0) to generate enrichment plots for Apc-, Wnt-,
Lgr5- and β-catenin-related target genes’ datasets.
Organoid culture. For organoid culture, intestinal epithelial cells were isolated as
detailed in the ‘Intestinal epithelial isolation and fractionation’ section below.
During cell fractionation step, fractions 3 and 4 were combined, washed with 20 ml
of Advanced DMEM/F-12 medium (ADF, Gibco) supplemented with 100 U/ml
penicillin, 100 µg/ml streptomycin, 2 mM L-Glutamine and 10 mM HEPES (Life
Technologies, 15630080). This was centrifuged at 300g for 3 min, supernatant was
discarded and the pellet was resuspended with 10 ml of supplemented ADF (from
now on, ADF) and filtered through a 70 µm cell strainer to obtain isolated crypt
fragments. Crypts were centrifuged at 700g for 10 min and pellet was carefully
resuspended with 500 µl of Cultrex PathClear Reduced Growth Factor BME (Bio-
Techne, 3533–010–02). In a pre-warmed 24-well plate, a volume of 20 µl/well of
BME was plated. The plate was incubated for 10 min at 37 °C to allow BME
solidification and 500 µl of growth medium was added. Growth medium was
composed of ADF, 1X N2 (Gibco, 17502048), 1X B27 (Gibco, 17504044), 50 ng/ml
EGF (Peprotech, 315–09–500) and 100 ng/ml Noggin (Peprotech, 250–38–500).
PDOs were established and grown as previously described57. Ethical approval for
human CRC organoid derivation was carried out under NHS Lothian Ethical
Approval Scottish Colorectal Cancer Genetic Susceptibility Study 3 (SOCCS3)
(REC reference: 11/SS/0109). Briefly, tumours were cut and washed with ADF in a
15 ml Falcon tube. Tumoral pieces were digested with 2 ml of digestion medium
containing 1700 µl ADF, 1 mg/ml Collagenase II (Sigma, C1764), 0.5 mg/ml
Hyaluronidase (Sigma, H3506) and 10 µM Y-27632 (Tocris, 1254). Digestion was
performed at 37 °C for 90 min with vigorous pipetting every 15 min to facilitate
digestion. Digestion was stopped by adding 100 µl of 1% BSA (bovine serum
albumin). Cells were passed through a 40 µm cell strainer to obtain single cells and
centrifuged for 3 min at 600g. Pellet was resuspended with 500 µl of BME and
plated in a pre-warmed 24-well plate. PDOs were grown in ADF medium con-
taining 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-Glutamine, 10 mM
HEPES, 1X Primocin, 1X B27, 1.25 mM NAC, 10 mM Nicotinamide, 50 ng/ml
EGF, 500 nM A83-01, 10 µM SB202190, 100 ng/ml Noggin, 1 µM PGE and 10 nM
gastrin. The organoid cultures were passaged every 3–4 days.
Depletion of Rac1b with an antisense morpholino. Two antisense morpholinos
were designed to specifically target the exon splice enhancer region of exon 4 in the
mouse and human Rac1/RAC1 transcript:
mRac1b PMO - GTCTATCTTTACCACATGTGTCTCC
hRAC1B PMO - TCCTTACCGTACGTTTCTCCAACCT
Binding led to the skipping of the exon 4 and prevented translation of RAC1B
protein. Morpholinos conjugated to an octa-guanidine dendrimer delivery moiety
(Vivo-Morpholino, PMO) were purchased from GeneTools (USA) and a non-
targeting morpholino (NT PMO) was used as control. For depletion of Rac1b in the
CMT93 cells, 2.5 × 105 cells were seeded in a 6-well plate and the medium was
supplemented with 2.5 µM of Rac1b PMO or NT PMO for 24 h. For depletion of
RAC1B in human organoids, these were treated with 1 µM hRAC1B PMO or NT
PMO for 96 h. Further experiments using 2D cells or 3D organoids deficient for
RAC1B were conducted following this pre-treatment with morpholino.
Morpholino was kept in the medium over the duration of the experiment.
Clonogenicity assays. Plated mouse organoids were washed and digested into
single cells through incubation with 500 µl of StemPro Accutase solution (Life
Technologies, A1110501) at 37 °C for 15 min. ADF was added to stop digestion and
cells were filtered through a 40 µm cell strainer. Cells were spun down for 5 min at
600g, the pellet was resuspended with 2 ml of ADF and cells were automatedly
counted using the Countess machine (Thermo Fisher). In all, 10,000 single cells
were plated per 5 µl BME drop, and a minimum of 4 drops was plated per each
genotype. Growth medium was added as usual and formed clones were counted
after 4 days. The percentage of clonogenic capacity was calculated as the average
percentage of spheres formed in each drop. This experiment was repeated with at
least 3 biological replicates and statistical differences were calculated. For PDOs,
organoids were digested with TripLE at 37 °C for 45 min with regular mixing.
Single cells were filtered and counted as above and 2500 cells plated per 5 µl BME
drop and a minimum of 4 drops was plated for each treatment group. Clone
formation was scored 14 days later.
Data plotting and statistical analysis. All statistical analyses and graphs were
performed using GraphPad Prism v7.0 software (La Jolla, USA) unless otherwise
stated. Student’s t-test was used for the comparison of two groups following
normality. In contrast, groups that did not follow normality were analysed with the
non-parametric Mann-Whitney test. Survival curves and percentage of survival
were calculated with a Log-rank (Mantel-Cox) test. Pearson correlation was used to
evaluate the correlation between two datasets, while Fisher’s test was used to assess
the association between two categories. All P values less than 0.05 were considered
statistically significant.
Generation of Rac1bfl allele. A conditional allele of Rac1b (Ensembl ID:
ENSMUSG00000001847 in mouse genome assembly GRCm38.p6) was created by
inserting loxP sites on either side of exon 4 (ENSMUSE00000648127; Chromosome
5: 143,509,597 - 143,509,653) of the Rac1b transcript (Rac1-202; ENSMUST0000
0100489.3). Small targeting vectors spanning the insertion sites of the loxP sites on
the 5ʹ and 3ʹ side of Rac1b exon 4 were synthesised (GeneArt). An F3-Neo cassette
and an Frt-Hygro cassette were inserted into the 5ʹ and 3ʹ loxP synthetic DNA
plasmids, respectively, by co-transfection into EL250 Escherichia coli58, which
express Flp recombinase under arabinose induction. The loxP FRT Hygro DNA
fragment bounded by the homology arms was excised and recombineered58 into a
mouse genomic DNA BAC clone (Source Biosciences) carrying the mouse Rac1b
gene in EL250 E. coli59. The Hygro cassette was then removed by arabinose-
induced Flp expression. Subsequently, the loxP F3 Neo DNA fragment was
introduced into the same Rac1b BAC clone by recombineering. A linearised
retrieval plasmid was generated by PCR of a p15A vector backbone with oligos
incorporating 70 bp Rac1b homology arms60. The modified Rac1b sequences were
retrieved from the BAC clone in EL250 E. coli by recombineering. The retrieved
plasmid represents the targeting vector with approximately 6.5 and 3.4 kb
homology arms. The targeting vector was linearised and transfected into HM1
mESCs61. Cells were selected under G418 (250 µg/ml) and surviving colonies
picked and screened for targeting by long range PCR (using the Roche Expand
Long Template PCR System) from within F3-Neo cassette to sequences beyond the
ends of the homology arms. Oligo sequences used to screen cells to ensure
appropriate targeting of the Rac1b gene were ATGTGGTATAGCTGTTCCCTGG
TC and CTAGAGCTTGCGGAACCCTTAATG (7.3 kb) for the 5ʹ side and
CTACTTCCATTTGTCACGTCCTGC and GTTGAGATGTGGTCCATGCTAA
GC (5.3 kb) for the 3ʹ side. The presence of the isolated loxP site was confirmed by
PCR with TTGGAGACACATGTGGTAAAGATAG and ACAGAACACCAGAG
TCAGAGAAGAG (424 bp) and confirmed by digestion of the PCR product with
XbaI, which is within the linked FRT site. Following identification of correctly
targeted clones, mouse lines were derived by injection of ES cells into C57BL/6J
blastocysts according to standard protocols. After breeding of chimeras, germline
offspring were identified by coat colour and the presence of the modified allele was
confirmed with the 3ʹ loxP primers described above. Mice were subsequently
crossed with a mouse line expressing Flpe (Tg(ACTFLPe)9205Dym) to delete the
selectable marker by recombination at the FRT sites62. Deletion with the selectable
marker was confirmed by PCR across the remaining F3 site with the oligos
CCCACAGATGAAACCAGGAG and GCTCAGCGTTCAGAAAGTGG (495 bp).
Immunohistochemistry. Intestinal tissue was harvested, flushed with PBS solution
and fixed as “Swiss-roll” sections in PFA for 24 h at 4 °C. For tumour scoring,
intestines were fixed in Methacarn (60% methanol, 30% chloroform and 10%
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glacial acetic acid). Tissue was automatedly processed through the Tissue-TeK VIP
infiltration Processor (Sakura) for paraffin embedding and cut into 5 µm sections
with the microtome (Leica). Standard IHC techniques were conducted during this
study. Antibodies used were as follows: BrdU, 1:500 (Bioss, bs-0489H), β-catenin,
1:50 (BD Biosciences, 610154), cleaved Caspase 3, 1:800 (R&D), Lyz1 (DAKO,
A009), Muc2 (Genetex, GTX100664), EGFRpY1068, 1:25 (Cell Signalling, 3777S),
EGFRpY1068, 1:400 (Abcam, ab40815) and ERK1/2pT202/Y204, 1:100 (Cell Signalling,
4370S). At least 3 different mice of each genotype were used as biological replicates
in every IHC experiment. Scoring of the staining was done blinded for evaluation
and representative images were selected. Images were digitalised using the Nano-
zoomer Digital slide scanner (Hamamatsu) and analysed with the viewer software
NDP.view2 (Hamamatsu). Scoring of tumour sections was automatedly performed
using the QuPath software (qupath.github.io), whilst proliferation scoring of
normal intestine was carried out manually.
BaseScope™ in situ hybridisation. A specific BaseScope™ probe was designed
against the exon 3–4 junction of the transcript variant 1 of Rac1
(NM_001347530.1), which included the following nucleotides: GTTGGAGACACA
TGTGGTAAAGATAGACCCTCCAGGGGCAAAGACAAGCCGATTGCCGA
CGTGTTC. The probe was purchased from Advanced Cell Diagnostics (ACD Bio-
Techne, UK) and BaseScope™ in situ hybridisation was conducted on formalin-
fixed intestine tissues embedded in paraffin blocks following company instructions.
For control of RNA integrity in tissue sections, sections were also hybridised with a
reference positive-control probe. Three different mice per each genotype were used
for the experiment and positive dots per tissue area were scored manually by blind
scoring. For false colour analysis, to enhance visibility of Basescope dots, the image
was split into red, green and blue channels in ImageJ. A threshold (180/255) was
set in the blue image, and the colour channels remerged.
Western blotting. Proteins from organoids and cellular pellets were extracted
using RIPA buffer (Sigma, R0278) supplemented with 1% of phosphatase and
protease inhibitors (Sigma, P0044 and P8340). BCA Protein Assay kit (Pierce) was
used to determine protein concentration. Here, 10 µg of denatured protein lysate
was separated by electrophoresis in 4–12% Bis-Tris protein gels (NuPage, Thermo
Fisher) and wet transferred onto methanol pre-activated nitrocellulose membrane.
Quick staining with Ponceau solution was used to evaluate transfer efficiency and
following PBST washes (PBS with 0.1% Tween, Sigma), membrane was blocked for
1 h at RT with 5% milk/PBST (dried milk, Marvel) or 3% BSA/PBST (BSA, Sigma)
when probing phosphorylated proteins. The membrane was incubated with pri-
mary antibody diluted in the blocking solution o/n at 4 °C and with anti-rabbit or
anti-mouse IgG (HRP linked, Cell Signalling) for 1 h at RT. Primary antibodies and
concentrations used were as follows: AKT, 1:2000 (Cell Signalling, 9272S);
AKTp5473, 1:3000 (Cell Signalling, 4060S); EGFR, 1:1000 (Cell Signalling, 2232S);
EGFRpY1068, 1:500 (Cell Signalling, 2234S); ERK1/2, 1:2000 (Cell Signalling,
4695S); ERK1/2pT202/Y204, 1:3000 (Cell Signalling, 4370S), NF-κB p65, 1:1000
(Abcam, ab7970), NF-κB p65pS536, 1:1000 (Cell Signalling, 3033S), Rac1b (Milli-
pore, 1:1000), Vinculin (Abcam, 1:5000), Streptavidin-HRP, 1:10,000 (Abcam,
ab7403), Myc-tag, 1:10,000 (Cell Signalling, 2276S) and β-actin, 1:5000 (Cell Sig-
nalling, 4970S). Antibody signal was detected by chemiluminescence using the ECL
Plus Substrate (Thermo Scientific) following product instructions, and the mem-
brane was developed at the darkroom with ECL hyperfilm (Amersham). Bands’
densitometry was assessed using FIJI (ImageJ). To allow subsequent use, mem-
branes were stripped by incubation with a Stripping solution (Millipore, 2504) for
15 min at RT.
RNA isolation. Intestinal tissue and tumours preserved in RNAlater (Sigma,
R0901) and pellets from tumour organoids or 2D cells were used to isolate RNA.
RNA extraction was conducted using the Qiagen RNeasy Mini Kit (Qiagen) and
the protocol was performed according to the manufacturer’s instructions. For
tissue RNA extraction, a homogenisation pre-step with stainless-steel beads and the
Qiagen Tissuelyser LT (Qiagen) was carried out. Genomic DNA contamination
was removed with the DNA-free removal kit (Ambion/Applied Biosystems,
AM1906) and RNA concentration was quantified with the Nanodrop ND-100
spectrophotometer (Thermo Fisher).
cDNA synthesis and quantitative qRT-PCR. Here, 1 µg of RNA was reverse
transcribed to cDNA using 4 µl of qScript cDNA SuperMix reagent (Quanta
Bioscience, 95048–100) in a final reaction volume of 20 µl. PCR cycling conditions
were as follows: 5 min incubation at 25 °C, DNA polymerisation at 42 °C for 30 min
and enzyme deactivation at 85 °C for 5 min. PCR product was diluted 1:10. For the
qRT-PCR experiment, a reaction mixture of 20 µl containing 10 µl of SYBR Master
mix (Life Technologies, A25742), 0.5 µM of each reverse and forward primer, 5 µl
of cDNA template and 4 µl of RNase-free water was prepared. The list of primers
used are shown in Table S1. Reactions were conducted in duplicate and β-actin was
used as a reference gene for CT-value normalisation. Amplification was conducted
using the CFX Connect Real-Time System machine (Bio-Rad) and cycling con-
ditions were as follows: a pre-incubation step of 95 °C at 15 min, followed by an
amplification step of 95 °C for 10 s, 60 °C for 30 s and 72 °C for 30 s repeated for 44
cycles, and a melting curve analysis from 65 °C to 95 °C in 0.5 °C intervals.
BioID protein interactome. A plasmid encoding the BirA* enzyme tagged to a
myc tag at the C-terminus was purchased from Addgene (Myc-BioID2-MCS
plasmid, 74223) and purified by Miniprep (Qiagen) according to the manu-
facturer’s protocol. Then, 5 µg of plasmid was digested with NheI-HF (NEB,
R3131) and EcoRI-HF (NEB, R3101S) restriction enzymes to introduce the Myc-
BioID2 sequence into the pLJM1-EGFP lentiviral vector (Addgene, 19319). Upon
plasmid ligation and transformation, successful colonies were grown and purified
by Miniprep. In parallel, Rac1b was purchased from GeneScript (OHu22224) and
Rac1 was amplified from normal murine small intestine tissue. Primers containing
the sequences of Eco-RI-HF and SacII-HF (NEB, R0175S) restriction enzymes were
used for Rac1b and Rac1 amplification. Primer sequences were as follows: Rac1/
Rac1b Forward (5ʹ-3ʹ): TTTTTGAATTCCAGGCCATCAAGTGTGTG and Rac1/
Rac1b Reverse (5ʹ-3ʹ): TATATCCGCGGTTACAACAGCAGGCATTTTCTC. For
amplification, Phusion DNA polymerase (NEB, M0530S) was used and the PCR
protocol consisted on a pre-incubation step of 98 °C for 4 min, 27 amplification
cycles composed of 45 s at 95 °C, 45 s at 59 °C, and 40 s at 72 °C and a final
elongation step of 7 min at 72 °C. After an A-tailing reaction with the FastTaq
polymerase (Roche, 12161508103) and 1 mM of dATP (PCR: 1 min at 95 °C and
30 min at 70 °C), the pGEM-T Easy Vector System (Promega, A1360) was utilised
to insert Rac1 and Rac1b sequences into the Myc-BioID2-containing lentiviral
vector. Blue-white screening with X-gal/IPTG plates was used to detected positive
(white) pGEM-T transformed colonies, which were grown and purified. PGEM-T
insert was digested and sequenced for verification. Lentiviral vector was digested
with EcoRI-HF and SacII-HF too and ligated with the pGEM-T inserts. Successful
colonies were sequenced and amplified by HiSpeed Plasmid Maxi kit (Qiagen). As
a BioID interaction control, an insert-free vector was also amplified. For the BioID
pull-down experiment, a total of 3 × 106 cells of the CMT93 cell line were seeded in
10 cm2 dish the day before transfection. Three plates were used per each condition
(Rac1-BirA, Rac1b-BirA and BirA), 24 µg of DNA per plate was used for trans-
fection, using 60 µg of Lipofectamine 2000 (Invitrogen, 11668030) and 40 h later,
transfection medium was replaced with 50 µM of Biotin (1 mM biotin stock:
0.0122 g biotin dissolved in 50 ml DMEM) in 10 ml of cell medium (Sigma, B4501).
Cells were incubated for 20 h and collected for protein extraction with 500 µl of
RIPA buffer per dish. Upon protein clarification, the lysate was incubated with 15
µl of neutralised Streptavidin Sepharose matrix (GE Healthcare, 17–5113–01) for 6
h at 4 °C on a rotator. Following incubation, the lysate was spun down at 1000g for
5 min and supernatant was carefully removed. Beads were gently washed with 1 ml
of wash buffer (50 mM TrisCl and 8M Urea, pH 7.4) for 8 min at RT on a rotator
and centrifuged at 1000g for 2 min. This washing step was repeated three times, the
last wash with a urea-free buffer. Beads’ pellets were a digested with Trypsin and
processed as previously described63. Mass spectrometry was done using a Lumos
Fusion (Thermo) mass spectrometer coupled to a RLS-nano uHPLC (Thermo).
Peptides were separated by a 40 min linear gradient from 5% to 30% acetonitrile,
0.05% acetic acid. Proteins were identified and quantified the MaxQuant software
suite using label-free quantification and searching against the mouse Uniprot
database. Proteins enriched in Rac1-BirA, Rac1b-BirA vs BirA Protein were
determined by >2-fold enrichment and P value < 0.05. NetworkAnalyst platform
with the IMEx database was used for the interactome analysis of the resultant
protein hits (networkanalyst.ca). To validate EGFR as a RAC1B-interacting pro-
tein, washed beads’ pellets were resuspended with RIPA and 10X DTT, run on a
western blot gel and probed against Streptavidin-HRP and EGFR. Lysate input was
used as a positive control.
Intestinal epithelial isolation and fractionation. Harvested small intestine was
washed with cold PBS, opened longitudinally and scrapped off with a coverslip to
discard villi. The intestine was cut into small pieces and transferred to a 50 ml
Falcon tube. Pieces were washed up and down several times with cold PBS, dis-
carding supernatant with debris, and these were incubated with 25 ml of 2 mM
EDTA for 30 min at 4 °C with agitation to allow crypt separation from surrounding
tissue. EDTA was discarded and intestinal pieces were gently washed with cold
PBS. Intestinal fractionation was initiated by adding 10 ml of cold PBS and thor-
oughly pipetting up and down several times. These 10 ml cell solutions were col-
lected, which contained loosened intestinal cells, and corresponded to fraction
number 1. This step was repeated three more times, the latter fractions being
enriched in crypt/stem cells. For fractionation and transcriptomic analysis, frac-
tions were independently spun down and pellets were used for RNA extraction and
qRT-PCR experiments. However, when evaluation of overall epithelial intestinal
cells was carried out, the four fractions were jointly collected and the cellular pellet
was used for either RNA or protein extraction.
Cells and cell culture. The cell line used in this study was the mouse rectal
carcinoma cell line CMT9364. A stock of 3–6 × 106 cells/ml was maintained over the
study in T25 or T75 cell flasks (Corning) in Dulbecco’s Modified Eagle’s Medium
(DMEM, Sigma) supplemented with 10% foetal calf serum and 1% of penicillin and
streptomycin (Life Technologies, 15140). When cells reached 80% confluency,
standard cell culture techniques were used for cell passaging and maintenance.
EGF stimulation experiment. In a 6-well plate, 2.5 × 105 CMT93 cells per well
were seeded. The day after, a medium solution with 20 ng/ml EGF was prepared
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and was added to the cells following 4 h serum starvation. Cells were collected after
5, 10, 15 and 30 min of EGF stimulation for protein extraction. A non-starved well
and a non-EGF-stimulated well were used as controls in each experimental group.
EGF uptake assay. CMT93 cells were subjected to knockdown of Rac1b using
mouse-specific PMOs targeting Rac1b, and a non-targeting control for 96 h. They
were serum-starved for 6 h before being treated with EGF-AlexFluor555 (20 ng/ml)
for the indicated times. Cells were then fixed in 4% PFA at room temperature (RT)
for 15 min, before being quenched with 100 mM Glycine-PBS for 10 min. Fol-
lowing three washes with PBS, cells were permeabilised (0.2% saponin, 5% BSA,
PBS pH 7.5) for 20 min at RT. Following 1 wash with IF buffer (0.2% Triton-X100,
0.05% Tween-20, PBS pH 7.5). Cells were then blocked in 3% BSA in IF buffer for
30 min, before being stained with α-EGFR (ab52894) in 1% BSA in IF buffer
overnight at 4 °C. Following three washes in IF buffer, cells were stained with α-
rabbit AlexaFluor488™ in 1% blocking solution for 45 min at RT. Cells were washed
three times in IF buffer, before stained in Fluoromount-G® with DAPI. Images
were taken on Nikon A1R confocal microscope. Images were analysed using
ImageJ.
EGFR-Rab5 co-localisation assay. CMT93 cells stably expressing pBabe-
mCherry-Rab5 construct (a gift from Dr. Noor Gammoh) were generated by ret-
roviral transduction in DMEM high-glucose media containing (8 µg/ml polybrene).
Two days post transduction, cells were selected for with puromycin (2 µg/ml) for
7 days. CMT93 cells were subjected to knockdown of Rac1b using mouse-specific
PMOs targeting Rac1b, and a non-targeting control for 96 h. Cells were serum-
starved for 6 h before being treated with EGF (20 ng/ml) for the indicated times.
Cells were then fixed in 4% PFA at RT for 15 min, before being quenched with 100
mM Glycine-PBS for 10 min. Following three washes with PBS, cells were per-
meabilised (0.5% Triton X-100, PBS pH 7.5) for 20 min at RT. Following 1 wash
with IF buffer (0.2% Triton-X100, 0.05% Tween-20, PBS pH 7.5). Cells were then
blocked in 3% BSA in IF buffer for 30 min, before being stained with α-EGFR
(ab52894) in 1% BSA in IF buffer overnight at 4 °C. Following three washes in IF
buffer, cells were stained with α-rabbit AlexaFluor488™ in 1% blocking solution for
45 min at RT. Cells were washed three times in IF buffer, before being stained in
Fluoromount-G® with DAPI. Images were taken on Nikon A1R confocal micro-
scope. Co-localisation was measured using Coloc2 plugin on ImageJ.
EGF tracking and lysosome-stained live cell imaging. CMT93 cells were sub-
jected to knockdown of Rac1b using mouse-specific PMOs targeting Rac1b, and a
non-targeting control for 96 h. They were serum-starved for 6 h before treatment.
Cells were stained with 25 nM LysoTracker™ Green DND-26 (Thermo Fisher
Scientific) for 30 min at 37 °C, followed by two washes in Live Cell Imaging
Solution (Invitrogen). Cell were then treated with 20 ng/ml EGF-AlexFluor555 and
imaged every 30 s for the indicated times using an Andor spinning disk confocal
microscope. EGF tracking was performed using TrackMate plugin on ImageJ. Co-
localisation was performed by manual scoring of EGF-555/LysoTracker double-
positive foci at each indicated time point. The total number of EGF-555 foci was
determined using ImageJ “Find Maxima” at setting 100. Percentage EGF-555 foci
co-localised with LysoTracker was calculated using these two values.
Modulation of EGFR signalling in tumour organoids. To inhibit EGFR with the
PD153035 small inhibitor (Sigma, SML0564), organoids were washed and split as
fragments by mechanically breaking the organoids with a P1000 instead of a P200.
A density of 100 fragments/µl of BME was plated in 15 µl BME drops. Following
24 h of plating, growth media was replaced with media containing either 1 µM of
PD15303 or 1% DMSO (Sigma) as control. Brightfield organoid pictures were
taken following 20 h of treatment. To assess RAC1B dependency for EGFR sig-
nalling activation, organoids plated as fragments were grown either with EGF-free
medium or with medium supplemented with EGF. Pictures were taken 72 h post
plating. For both experimental setups, images were used to assess the organoid area
using ImageJ.
Cetuximab treatment of patient-derived organoids. Human colorectal orga-
noids derived from liver metastases (C001 and C002) were cultured in ADF
medium containing 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-Gluta-
mine, 10 mM HEPES, 1X Primocin, 1X B27, 1.25 mM NAC, 10 mM Nicotinamide,
50 ng/ml EGF, 500 nM A83-01, 10 µM SB202190, 100 ng/ml Noggin, 1 µM PGE
and 10 nM gastrin. Organoids were passaged by breaking into small fragments and
replating. RAC1B was depleted by treatment with 1 µM hRAC1B PMO or NT PMO
for 96 h. After 96 h, the media was replaced with fresh media containing 1 µM
hRAC1B PMO or NT PMO plus or minus 30 μg/ml cetuximab (Selleck, A2000).
Pictures were taken 96 h post treatment. For all four experimental setups, images
were used to assess the organoid area using ImageJ.
Software. The following software was used for data analysis: Microsoft Office
Excel 365, GraphPad Prism v7.0 and v8.3.1, RNAseq analysis - TrimGalore 0.6.5,
cutadapt 3.2, tophat 2.1.1 and cuffdiff 2.2.1, ImageJ 1.52p, kallisto 0.45, and
DESeq2 v1.30.1.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
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